Jiangsu Sihuan Bioengineering Co Ltd. Stock Analysis 000518.SZ

Jiangsu Sihuan Bioengineering Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceutical products. The company is headquartered in Wuxi, Jiangsu and currently employs 232 full-time employees. The firm operates its businesses through three segments. The Pharmaceutical segment is mainly engaged in the production and sales of injections and medicines. The Forestry segment is mainly engaged in greening construction and forestry sales. The Others segment is mainly engaged in leasing and other businesses. The firm's main products include Delusheng (recombinant human interleukin-2 for injection), Xindelusheng (recombinant human interleukin-2 injection) and others. The firm's products are mainly used for the treatment of renal cancer, malignant melanoma, and cancerous pleural and abdominal effusions. The firm mainly operates its businesses in the domestic and overseas markets.